Day One Biopharmaceuticals said Tuesday the Food and Drug Administration approved its pill for one of the most common forms of childhood brain tumors, called pediatric low-grade glioma.
The authorization is particularly notable because industry has historically developed few drugs for children with cancer, focusing instead on adults and often only years later testing their molecules in younger patients. Day One was established by Sam Blackman, a pediatric oncologist and longtime drug executive, and venture capitalist Julie Grant to try to find a model to develop drugs for children.Â
The drug, previously known as tovorafenib, will be marketed as Ojemda. Day One has not yet disclosed a price.
Ojemda targets a protein called BRAF, which is the most common mutation driving such tumors, and is only indicated only for patients with a confirmed mutation.
Click this link for the original source of this article.
Author: Jason Mast
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.